Rich Heyman's Metacrine tacks on another $65M to tackle a superior NASH drug
Just six months after unwrapping its B round to push a NASH drug through the clinic, San Diego’s Metacrine is ramping up efforts towards that cause with a $65 million infusion of cash.
The money comes from a long list of new investors led by Venrock, and it brings the startup’s total VC haul to $125 million since its 2015 founding. The company was co-founded by serial entrepreneur Rich Heyman — the man behind Aragon and Seragon, which both sold for over $1 billion in the span of one year — and Ronald Evans, the Salk scientist behind a slew of biotech companies, including Ligand Pharmaceuticals and the recently acquired Mitobridge. Both Evans and Heyman are still involved with Metacrine: Heyman is chairman, while Evans sits on the board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
